Filing Flows › Vivos Therapeutics (VVOS) › Q4 2025
Vivos Therapeutics (VVOS) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Apr 15, 2026
Vivos Therapeutics (VVOS) reported revenue of $3.8M for the fourth quarter 2025 (Q4 2025), +3% from a year earlier and -44% from the quarter before. Operating margin was -166.9%, net loss $6.9M (180.3% of revenue).
Vivos Therapeutics, Q4 2025: revenue $3.8M (+3% year over year), operating margin -166.9%, net loss $6.9M, operating cash flow −$3.8M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.8M | -44% | +3% |
| Operating profit | −$6.4M | — | — |
| Net earnings | −$6.9M | — | — |
| Operating cash flow | −$3.8M | — | — |
What changed
Revenue was $3.8M in Q4 2025, up 3% year over year and down 44% from the previous quarter. Sleep Testing Services was the largest line at 61% of revenue.
Gross margin was 78.1%, up 21.4 points from Q4 2024. Operating costs exceeded revenue by $6.4M, an operating margin of -166.9%. Operating expenses grew 91% against revenue growth of 3%. The fastest-growing cost line was Other operating costs (+207%). The quarter ended with a net loss of $6.9M, wider than the previous quarter's $5.4M loss.
Operating cash flow was −$3.8M. Non-cash charges added back $442K of depreciation and amortization and $47K of share-based compensation. Working capital and other items added $2.6M. Capital expenditures of $1.5M exceeded it, leaving free cash flow of −$5.3M.
Questions
What was Vivos Therapeutics' revenue in the fourth quarter 2025?
Vivos Therapeutics (VVOS) reported revenue of $3.8M for the fourth quarter 2025 (Q4 2025), +3% from a year earlier and -44% from the quarter before.
Was Vivos Therapeutics profitable in the fourth quarter 2025?
Operating loss was $6.4M (-166.9% of revenue) and net loss $6.9M.
Source: Vivos Therapeutics 10-K on SEC EDGAR.